Kyongbo Pharmaceutical Co Ltd (214390) — Capital Reinvestment Ratio
Kyongbo Pharmaceutical Co Ltd (214390) has a Capital Reinvestment Ratio of 8.69x as of March 2026, meaning it reinvests 9% of its operating cash flow (₩1.79 Billion) in capital expenditures (₩15.55 Billion). Check 214390 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Kyongbo Pharmaceutical Co Ltd Capital Reinvestment Ratio (2014–2025)
This chart tracks Kyongbo Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 11 annual periods. For the full cash flow conversion analysis, see Kyongbo Pharmaceutical Co Ltd (214390) cash flow conversion.
Annual Capital Reinvestment Ratio for Kyongbo Pharmaceutical Co Ltd (2014–2025)
Year-by-year Capital Reinvestment Ratio for Kyongbo Pharmaceutical Co Ltd from 2014 to 2025. See how much free cash does Kyongbo Pharmaceutical Co Ltd generate to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 5.58x | ₩7.46 Billion | ₩41.61 Billion | ▼ -93.7% |
| 2024 | 88.35x | ₩149.12 Million | ₩13.18 Billion | ▲ +3835.0% |
| 2023 | 2.25x | ₩4.84 Billion | ₩10.88 Billion | ▲ +72.5% |
| 2022 | 1.30x | ₩10.13 Billion | ₩13.18 Billion | ▲ +27.7% |
| 2021 | 1.02x | ₩17.97 Billion | ₩18.32 Billion | ▲ +70.5% |
| 2020 | 0.60x | ₩20.80 Billion | ₩12.44 Billion | ▼ -39.1% |
| 2019 | 0.98x | ₩23.67 Billion | ₩23.25 Billion | ▲ +242.7% |
| 2017 | 0.29x | ₩25.81 Billion | ₩7.40 Billion | ▼ -63.1% |
| 2016 | 0.78x | ₩25.33 Billion | ₩19.68 Billion | ▼ -87.9% |
| 2015 | 6.43x | ₩4.24 Billion | ₩27.26 Billion | ▲ +434.9% |
| 2014 | 1.20x | ₩16.04 Billion | ₩19.28 Billion | — |